DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 28, 2025

vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible. This innovative technology maximizes operational efficiency, enhances staff expertise, and delivers better patient outcomes, making it a wise long-term investment. 2012) 380:2095128.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

DAIC

FEBRUARY 14, 2024

Recent shifts in third-party payer reimbursement, led by the Centers for Medicare and Medicaid , have resulted in continued trends of minimally invasive cardiac procedures on stable patients increasingly being performed outside of a hospital setting.

Outpatient 105

Outpatient Hospital Reimbursement Medicaid 105

DAIC

MARCH 7, 2024

Despite improvements with current medications and devices, heart failure remains at epidemic proportions and we now have an exciting opportunity for a therapy to improve important, objective outcomes, such as mortality and hospital re-admissions rates. “We The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

DAIC

JULY 25, 2024

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

GEMMS

APRIL 8, 2024

Established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) , the MIPS Program is pivotal in determining Medicare payment adjustments for healthcare practices. What is MIPS? Additionally, the 2024 final rule retains the methodology for measuring scores and achieving points with no notable alterations.

Medicare 52

Medicare Innovation Medicaid Patient Care 52

American College of Cardiology

FEBRUARY 1, 2025

Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. In recent years, numerous health care challenges have been tackled, some making headlines, while others quietly escalate under the radar – like polypharmacy.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40